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ABSTRACT 
Extracorporeal membrane oxygenation (ECMO) has emerged as an effective 
mechanical support following cardiac surgery with respiratory and cardiac failure. 
However, there are no clear indications for ECMO use after pediatric cardiac surgery. 
We retrospectively reviewed medical records of 76 pediatric patients [mean age, 10.8 
months (0–86); mean weight, 5.16 kg (1.16–16.5)] with congenital heart disease who 
received ECMO following cardiac surgery between January 1997 and October 2010. 
Forty-five patients were treated with aggressive ECMO approach (aggressive ECMO 
group, April 2005−October 2010) and 31 with delayed ECMO approach (delayed 
ECMO group, January 1997−March 2005). Demographics, diagnosis, operative 
variables, ECMO indication, and duration of survivors and non-survivors were 
compared. Thirty-four patients (75.5%) were successfully weaned from ECMO in 
aggressive ECMO, and 26 (57.7%) were discharged. Conversely, eight patients (25.8%) 
were successfully weaned from ECMO in delayed ECMO, and two (6.5%) were 
discharged. Forty-five patients with shunted single ventricle physiology (aggressive: 29 
patients, delayed: 16 patients) received ECMO, but only 15 (33.3%) survived off and 
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were discharged. Survival rate of aggressive ECMO was significantly better compared 
with delayed ECMO (p<0.01).  Also, ECMO duration was significantly shorter among 
aggressive ECMO survivors (96.5 ± 62.9 h, P < 0.01). Thus, aggressive ECMO 
approach is a superior strategy compared to delayed ECMO approach in pediatric 
cardiac patients. Aggressive ECMO approach improved our outcomes of neonatal and 
pediatric ECMO. 
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INTRODUCTION 
Extracorporeal membrane oxygenation (ECMO) has emerged as an effective 
mechanical support following cardiac surgery with respiratory and cardiac failure. In 
1976, Bartlett et al.1 reported the successful use of ECMO for a neonatal patient with 
respiratory failure, and ECMO has since been used effectively for a variety of 
indications including preoperative hemodynamic support, low cardiac output after 
cardiopulmonary bypass (CPB), sudden cardiac arrest, and as a bridge to heart 
transplantation.2 The Extracorporeal Life Support Organization (ELSO) registry reports 
that the rates of survival off ECMO and survival to discharge among neonatal cardiac 
patients are 59% and 39%, respectively; in pediatric patients, these values are 62% and 
46%, respectively. The rates of survival off ECMO and to discharge among neonates 
subject to extracorporeal cardiopulmonary resuscitation are 63% and 37%, and in 
pediatric patients these rates are 52% and 38%, respectively.3 Outcomes of ECMO have 
been developing and still have been keeping the improvement scope for better outcomes, 
especially in patients with congenital heart disease.  
In our institute, we did not have any criteria for ECMO introduction until 
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March 2005, but we changed our strategy of ECMO therapy and introduced an 
aggressive approach toward indications for ECMO from April 2005 wherein we did not 
hesitate to introduce ECMO. Before we had changed our strategy of ECMO therapy in 
April 2005, we had felt the negative image of ECMO because of our poor results of 
survival off ECMO in patients with congenital heart disease.  
The purpose of this study was to evaluate the effects of this aggressive 
approach of ECMO initiation since we changed our strategy of ECMO compared with 
the previously followed delayed approach for introducing ECMO after pediatric cardiac 
surgery by reviewing our single center experiences. 
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MATERIALS AND METHODS 
We retrospectively reviewed medical records of 76 pediatric patients with 
congenital heart disease who received ECMO following cardiac surgery between 
January 1997 and October 2010 at Okayama University Hospital, Japan.  
Two groups were compared those who were treated with the aggressive 
ECMO approach (45 patients from April 2005 to October 2010), and those were treated 
with the delayed ECMO approach (31 patients from January 1997 to March 2005). The 
aggressive ECMO approach was defined as commencement of ECMO as early as 
possible before end-organ dysfunction or complete circulatory collapse, and without 
hesitate to introduction of ECMO. The outcomes were categorized as follows: survived 
off ECMO (successful weaning from ECMO support), survival to hospital discharge, 
and survival during outpatient follow-up. Demographics, diagnosis, operative variables, 
and ECMO indication and duration of survivors and non-survivors were compared. We 
compared the lactate level of both groups before and 2 hours later introduced ECMO. 
We defined the indications for aggressive ECMO as follows: mean arterial 
blood pressure less than 35 mmHg, anuria, high lactate level (greater than 5.0 mmol/L) 
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and acidosis with pH less than 7.3, hypoxia with arterial oxygen saturation less than 
60% with 100% FiO2 (fraction of inspired oxygen) on mechanical ventilatory support. 
ECMO was established via a median sternotomy, and cannulation of the ascending aorta 
or inominate artery for return, and drainage via a 3-mm polytetrafluoroethylene graft to 
the right atrium (in cases of after a Norwood stage 1 procedure). For the patients with a 
right ventricle (RV) to pulmonary artery (PA) shunt after a Norwood stage 1 procedure 
in hypoplastic left heart syndrome, we opened the RV-PA shunt and controlled the 
pulmonary blood flow by the degree of clipping the shunt.  
We used a hollow fiber membrane oxygenator (Biocube®; Nipro, Osaka, 
Japan) and a centrifugal pump (Gyro®; Kyocera, Kyoto, Japan) with a 6-mm heparin 
coated tube (Biomate®; Toyobo, Osaka, Japan) for ECMO device. The initial ECMO 
flow rate was set at 150–180 ml/kg/min. Anticoagulation was accomplished by drip 
infusion of heparin sodium to maintain an activated clotting time of 150−200 seconds. 
Hemoglobin concentration was maintained above 10 g/dL by transfusion of packed red 
blood cells during full support. We maintained the bladder temperature at 35°C and 
applied minimal ventilatory support during ECMO. The intrathoracic cavity was 
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irrigated with sterile warmed normal saline every 3 days.  
We tried to wean the patient off ECMO when the lactate level was less than 
2.0 mmol/L, the urine output was increased to equal or greater than 1.0 ml/kg/h for as 
long as 24 h, and the arterial pulse pressure was increased to equal or greater than 10 
mmHg. We started inotropic agents for 6 h and gradually reduced the ECMO flow rate 
under stable hemodynamic conditions. We weaned the patient off ECMO within 12 h. 
Descriptive statistics are expressed as mean ± standard deviation (s). The 
χ2test for a (2 × N) table, Kruskal-Wallis test and student t test were used to evaluate 
differences between groups for statistical significance. A P-value of <0.05 was 
considered to have statistical significance. 
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RESULTS 
The mean age of all patients was 10.8 months (range, 0 days−86 months) and 
the mean weight was 5.16 kg (1.16−16.5 kg). The demographics data of both aggressive 
ECMO and delayed ECMO was shown in Table 1. Cardiopulmonary bypass time 
(aggressive: 187.20 ± 117.48 min, delayed: 194.90 ± 115.33; P=0.400) and aortic cross 
clamp (aggressive: 79.93 ± 44.01 min, delayed: 64.62 ± 44.78 min; P=0.105) time 
during surgery were not significantly difference. Thirty-four patients (75.5%) from 
aggressive ECMO (n = 45) survived off ECMO and 26 patients (57.7%) survived to 
hospital discharge (Table 2). Eight patients (25.8%) from delayed ECMO (n = 31) 
survived off ECMO and 2 patients (6.5%) survived to hospital discharge (Table 2). 
Thirty-one patients (31/76, 40.8%) had biventricular physiology and 45 patients (45/76, 
59.2%) single ventricle physiology. All the patients with single ventricle physiology 
treated with delayed ECMO died in the hospital (Table 3). The patients with 
biventricular physiology treated with the aggressive ECMO had significantly better 
results than the other groups. The patients who survived off ECMO and hospital 
discharge following the aggressive ECMO had significantly shorter ECMO duration 
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than those following delayed ECMO (Table 4). 
The timing of introduction is shown in Table 5. When ECMO was indicated 
for patients in the intensive care unit (ICU), aggressive ECMO group had a significantly 
shorter duration of ECMO days after operation than that of delayed ECMO group.  
Our indication criteria for ECMO are shown in Table 5. In aggressive ECMO 
group, low cardiac out put syndrome was the significant reason for indication. In 
delayed ECMO group, cardiac arrest and hypoxia were the two major reasons for 
ECMO.  
The lactate level of before and after introduced ECMO was shown in Table 6. 
The lactate level of both groups was not significantly difference. 
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DISCUSSION 
ECMO support following pediatric cardiac surgery provides effective support 
for postoperative cardiac and pulmonary dysfunction refractory to conventional medical 
management.4 ECMO is an advanced therapy for acute cardiac and/or respiratory failure 
associated with congenital heart disease and pulmonary disease.5 Indications for ECMO 
are affected by many factors, including ventricular function, magnitude of conventional 
inotropic support, and pulmonary function. No standard indication criteria or 
management guidelines have been established for ECMO in congenital heart disease 
because of its complex nature and specificity of use.6  
At our institution, in April 2005, the approach for ECMO was changed from a 
delayed ECMO approach where patients were managed without ECMO as long as 
possible to an aggressive ECMO approach where patients were indicated for ECMO as 
early as possible before a catastrophic event such as cardiac arrest occurred. In our 
results, the aggressive ECMO approach revealed a significantly better result in terms of 
ECMO survival and survival to hospital discharge than delayed ECMO group.  
Ungeleider et al. have suggested that mechanical assistance should be routine 
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after Norwood staged 1 procedure, and described aggressive approach of mechanical 
assistance improved hospital survival rate.7 Cooper et al. have suggested that initiation 
of ECMO support should be based on “urgent” rather than “emergency” criteria, i.e., 
before the occurrence of end-organ dysfunction or circulatory collapse.8 The risk factors 
for mortality due to ECMO are as follows: age below 1 month, male gender, long 
duration of mechanical ventilation support prior to introducing ECMO, and 
development of renal or hepatic dysfunction during ECMO.6, 9 Following pediatric 
cardiac surgery, it is critical to maintain both systemic and pulmonary blood flow. The 
advantage of aggressive ECMO is prevention of ventilator-induced lung injury caused 
by respiratory care injuries resulting from setting up mechanical ventilation. 
Booth et al. demonstrated that the survival of cardiac patients supported by 
ECMO is associated with indication and cardiac diagnosis.2 The ELSO registry reported 
that rates of survival to weaning from ECMO and survival to hospital discharge were 
59% and 39% in neonatal patients, and 62% and 46% in pediatric patients, 
respectively.3 In our study, rates of survival to weaning from ECMO and survival to 
hospital discharge were 75.5% and 57.7%, respectively. Our aggressive ECMO 
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approach was shown to be superior to that of the ELSO registry average. Hence, the 
aggressive ECMO approach may result in better ECMO outcomes for patients with 
congenital heart disease than delayed ECMO approach. 
Patients with single ventricle physiology, especially those with hypoplastic 
left heart syndrome, had a significantly higher mortality rate than those with 
biventricular physiology.6, 10 In our review, aggressive ECMO approach brings better 
outcomes at least patients with single ventricle physiology than delayed ECMO 
approach. 
It is well known that long ECMO duration increases the risk of complications 
such as bleeding, hemolysis, and systemic inflammatory syndrome. Long ECMO 
duration also increases the mortality rate associated with ECMO, and may affect the 
progression of multiple organ dysfunction and have a negative influence on 
immunological systems.6, 10, 12, 13 A previous study of ours as well as one by Baslaim et 
al. clearly indicated that patients with long ECMO duration (more than 3 days) may 
benefit less from ECMO support and may have an increased risk of mortality.6, 10  
In general, the purpose of pediatric ECMO as a mechanical circulatory 
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support following cardiac surgery is recovery of cardiac function by unloading the right 
and left ventricle preloads and increasing the ECMO flow rate as well as resting the 
lungs from the high demand for oxygen saturated blood by the body. On the other hand, 
increasing the ECMO flow rate increases the left ventricular afterload and wall stress. 
These ECMO mismatches have a negative impact and outcome during pediatric ECMO 
following cardiac surgery. Hence, not only early introduction of ECMO but also early 
weaning as early as possible from ECMO might help to get better outcomes. 
Several groups have reported improved survival in patients placed on ECMO 
in the operating room compared with those cannulated in the ICU.12, 13 Chaturvedi 
reported avoidance of severe end-organ damage before restoration of adequate 
perfusion to pursue an aggressive approach for early indication of ECMO with the aim 
of reducing the morbidity and mortality associated with prolonged periods of 
hypoperfusion and cardiac arrest.13 Our review also showed that it might be better to 
choose an aggressive ECMO approach of early introduction of ECMO before progress 
to multiple organ dysfunctions could possibly prevent cardiac arrest, which results a 
poor outcome. The ELSO registry report in 2009 showed a poor outcome for 
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extracorporeal cardiopulmonary resuscitation after cardiac arrest, with survival rates of 
26% in neonates, 47% in infants, and 39% in pediatric patients.3  
In conclusion, we recommend an aggressive ECMO approach following 
pediatric cardiac surgery, which requires early introduction and early discontinuation of 
ECMO support before end-organ dysfunction and circulatory collapse, rather than the 
conventional approach of delaying ECMO introduction. Aggressive ECMO approach 
improved outcomes of ECMO therapy in our institution. 
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Figure Legend 
Table 1: The demographics data of aggressive and delayed ECMO groups 
AS, aortic stenosis; DORV, double outlet right ventricule; TOF, tetralogy of fallot; PA, 
pulmonary atrisia; VSD, ventricular septal defect; TAPVC, total anomalous pulmonary 
venous connection; CoA, coactation of aorta; BWG, Bland-White-Garland; HLHS, 
hypoplastic left heart syndrome; SA, single atrium; SV, single ventricle; TA, tricuspid 
atrisia; DILV, double inlet left ventricule; PA, pulmonary atrisia; IVS, intact ventricular 
septum; IAA, interrupted aortic arch; MS, mitral stenosis; AVSD, atrioventricular septal 
defect; TGA, transposition of great arteries; PTA, persistent truncus arteriosus  
Table 2: Comparison of Extracorporeal membrane oxygenation (ECMO) 
decannulation and hospital discharge ratio  
Table 3: Comparison of Patients with Biventricular and Single ventricle 
physiology 
Table 4: Comparison of ECMO duration (mean ± s)  
Table 5: Patients Profiles 
This table shows the comparison between groups A and B in terms of time to 
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introduction of ECMO and indication criteria for ECMO. 
OR: operating room; ICU: intensive care unit; LCOS: low cardiac output syndrome; 
n.s.: non-significant difference. Numbers inside () indicate the number of patients. 
Table 6: The lactate level of before and after ECMO 
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Table 1. 
